TAGRAXOFUSP-ERZS for Blastic plasmacytoid dendritic cell neoplasia: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 273 adverse event reports in the FDA FAERS database where TAGRAXOFUSP-ERZS was used for Blastic plasmacytoid dendritic cell neoplasia.
Most Reported Side Effects for TAGRAXOFUSP-ERZS
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Capillary leak syndrome | 110 | 25.1% | 35 | 55 |
| Pyrexia | 45 | 10.3% | 10 | 17 |
| Death | 36 | 8.2% | 36 | 3 |
| Disease progression | 33 | 7.5% | 16 | 6 |
| Thrombocytopenia | 26 | 5.9% | 7 | 10 |
| Blood albumin decreased | 24 | 5.5% | 2 | 8 |
| Acute kidney injury | 23 | 5.3% | 8 | 11 |
| Off label use | 23 | 5.3% | 12 | 6 |
| Weight increased | 22 | 5.0% | 8 | 6 |
| Transaminases increased | 21 | 4.8% | 6 | 6 |
| Tumour lysis syndrome | 21 | 4.8% | 9 | 3 |
| Sepsis | 19 | 4.3% | 9 | 14 |
| Liver function test increased | 18 | 4.1% | 3 | 5 |
| Hypoalbuminaemia | 17 | 3.9% | 2 | 7 |
| Hypotension | 17 | 3.9% | 7 | 10 |
Other Indications for TAGRAXOFUSP-ERZS
Other Drugs Used for Blastic plasmacytoid dendritic cell neoplasia
DEXAMETHASONE (140)
VENETOCLAX (123)
CYCLOPHOSPHAMIDE (116)
VINCRISTINE (114)
DOXORUBICIN (98)
METHOTREXATE (87)
CYTARABINE (69)
AZACITIDINE (65)
PREDNISONE (45)
ETOPOSIDE (35)